Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 709

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 6
Chunk 709
---
ity Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1  $97,583,906  $5,233  $(91,930,152) $5,658,989 Preferred stock conversion to common stock  (123.909)  (1)  -   -   5   -   1   -   -   - Common stock issued for cash  -   -   -   -   3,671   -   1,148,470   -   -   1,148,470 Common stock issued for warrant exercise  -   -   -   -   520,922   52   5,368,312   -   -   5,368,364 Common stock issued for cashless warrant exercise  -   -   -       6,327   -   1,320,567   -   -   1,320,567 Fair value of vested common stock  -   -   -   -   46   -   80,000   -   -   80,000 Fair value of vested stock options  -   -   -   -   -   -   491,924   -   -   491,924 Stock payable towards preference dividend  -   -   -   -   -   -   5,233   (5,233)  -   - Net loss  -   -   -   -   -   -   -   -   (11,507,947)  (11,507,947)Balance as of December 31, 2024   17.488  $-   -  $-   536,908  $53  $105,998,412  $-  $(103,438,099) $2,560,366 

The accompanying notes are an integral part of these consolidated financial statements. 

 F-4 

ENDRA Life Sciences Inc.

Cons